Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia

Chae, Young Kwang; Trinh, Long; Jain, Preetesh; Wang, Xuemei; Rozovski, Uri; Wierda, William G.; Keating, Michael J.; Estrov, Zeev

doi:10.1182/blood-2013-07-517102

Cited by 22 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One study found increased event-free survival among FL patients who used statins [24]. In another study, use of statins alone did not affect progression-free or overall survival of CLL, but risk was reduced by 60% when statins were combined with aspirin [36]. Neither overall survival (PHR = 1.02, 95% CI 0.99-1.06, Figure 3) nor event-free-survival (PHR = 0.99, 95% CI 0.87-1.12) of DLBCL patients was associated with statin use (Supporting Information Figure S4).…”

Section: Resultsmentioning

confidence: 99%

Associations between statin use and non‐Hodgkin lymphoma (NHL) risk and survival: a meta‐analysis

Mneina

Johnston

et al. 2015

Hematological Oncology

View full text Add to dashboard Cite

Evidence on the effect of statin use on non-Hodgkin lymphoma (NHL) is not clear. We conducted a systematic review and meta-analysis to examine the associations between statin use and NHL risk and survival. We searched multiple literature sources up to October 2014 and identified 10 studies on the risk of diagnosis with NHL and 9 studies on survival. Random effects model was used to calculate pooled odds ratio (PORs) for risk and pooled hazard ratio (PHR) for survival. Heterogeneity among studies was examined using the Tau-squared and the I-squared (I ) tests. Statin use was associated with reduced risk for total NHL (POR = 0.82, 95% CI 0.69-0.99). Among statin users, there was a lower incidence risk for marginal zone lymphoma (POR = 0.54, 95% CI 0.31-0.94), but this was not observed for other types of NHL. However, statin use did not affect overall survival (PHR = 1.02, 95% CI 0.99-1.06) or event-free survival (PHR = 0.99, 95% CI 0.87-1.12) in diffuse large B-cell lymphoma. There is suggestive epidemiological evidence that statins decrease the risk of NHL, but they do not influence survival in NHL patients. Copyright © 2015 John Wiley & Sons, Ltd.

show abstract

Section: Resultsmentioning

confidence: 99%

Associations between statin use and non‐Hodgkin lymphoma (NHL) risk and survival: a meta‐analysis

Mneina

Johnston

et al. 2015

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Although statins did not affect the clinical outcome of newly diagnosed patients with early stage CLL [87], retrospective data analysis suggested that the administration of statins and aspirin was associated with improved outcome in patients with relapsed/refractory CLL treated with salvage chemotherapy [88]. …”

Section: Targeting Metabolic Pathways In Cll Cellsmentioning

confidence: 99%

Metabolism pathways in chronic lymphocytic leukemia

Rozovski

Hazan‐Halevy

Barzilai

et al. 2015

Leukemia & Lymphoma

Self Cite

View full text Add to dashboard Cite

Alterations in CLL cell metabolism have been studied by several investigators. Unlike normal B lymphocytes or other leukemia cells, CLL cells, like adipocytes, store lipids and utilize free fatty acids (FFA) to produce chemical energy. None of the recently identified mutations in CLL directly affects metabolic pathways, suggesting that genetic alterations do not directly contribute to CLL cells’ metabolic reprogramming. Conversely, recent data suggest that activation of STAT3 or downregulation of microRNA-125 levels plays a crucial role in the utilization of FFA to meet CLL cells’ metabolic needs. STAT3, known to be constitutively activated in CLL, increases the levels of lipoprotein lipase that mediates lipoprotein uptake and shifts CLL cells’ metabolism towards utilization of FFA. Herein we review the evidence for altered lipid metabolism, increased mitochondrial activity, and formation of reactive oxygen species in CLL cells, and discuss possible therapeutic strategies to inhibit lipid metabolism pathways in patient with CLL.

show abstract

“…The authors were intrigued by a recent case-control study in Canada that demonstrated that CLL patients have more dyslipidemia than age-matched controls, and that CLL patients who took HMG-CoA reductase inhibitors (“statins”) had improved survival compared to CLL patients who did not take these medications, which confirmed similar results in smaller CLL cohorts (Chae et al, 2014, Friedman et al, 2010, Mozessohn et al, 2017). Together with the story regarding lipoprotein lipase, these clinical data beg the question of if and how LDLs affect CLL cells.…”

mentioning

confidence: 83%

Lipids and Their Effects in Chronic Lymphocytic Leukemia

Friedman

2017

EBioMedicine

View full text Add to dashboard Cite

Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia

Cited by 22 publications

References 9 publications

Associations between statin use and non‐Hodgkin lymphoma (NHL) risk and survival: a meta‐analysis

Associations between statin use and non‐Hodgkin lymphoma (NHL) risk and survival: a meta‐analysis

Metabolism pathways in chronic lymphocytic leukemia

Lipids and Their Effects in Chronic Lymphocytic Leukemia

Contact Info

Product

Resources

About